


Remarks

The foregoing amendments to the specification were made to correct inadvertent typographical errors with regard to amino acid positioning in the text of the specification and to correlate the text of the amended specification with the figures as originally filed in the application. In addition, a substitute sequence listing is submitted herewith to correct inadvertent typographical errors with regard to amino acid positioning in the previously submitted sequence listing. Claims 40 and 45 have been amended such that reference to the inadvertent errors in the sequence listing have been deleted. Support for the amendments can be found throughout the originally filed specification, for example, at least on page 26, line 27 to page 27, line 29, and in originally filed Figure 3F, which was derived from the inventor's publication, Kawasaki et al., 282 Sci. 2275-79 (1998) (copy enclosed). This publication was incorporated by reference on page 4, lines 1-2 of the specification as originally filed, and corroborates the identity of the GenBank accession numbers for the hcAMP-GEFI and hcAMP-GEFII sequences on page 2279 of the publication. As stated above, a Supplemental Information Disclosure Statement and PTO 1449 form reciting the reference, along with a copy of the reference, are submitted herewith. Applicants submit that no new matter is introduced with this supplemental amendment and respectfully request entry of the amendments and the substitute sequence listing. Applicants believe the application is in condition for allowance and request early and favorable action.

Respectfully submitted,



Jennifer G. Moitoso
Attorney for Applicants
Kirkpatrick & Lockhart
Nicholson Graham LLP
75 State Street
Boston, MA 02109

Date: June 9, 2005
Reg. No. 51,752

Tel.: 617-261-3285